Quarterly report pursuant to Section 13 or 15(d)

Licenses Agreements - Narrative (Details)

v3.23.3
Licenses Agreements - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Sep. 26, 2023
Sep. 08, 2023
Aug. 31, 2023
Apr. 27, 2023
Feb. 28, 2023
Oct. 11, 2022
Jun. 30, 2021
Oct. 31, 2015
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Research and Development Expense                 $ 20,348 $ 29,902 $ 91,995 $ 99,755
Stock offering, price per share         $ 5.25              
Expenses recognized                 20,348 29,902 91,995 99,755
Journey | Maruho Co Ltd                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Upfront fees payment     $ 19,000                  
Payments of milestones     45,000                  
Journey | Maruho Co Ltd | Maruho Achievement of Net Sales of 4 Billion Yen Of Rapifort During Single Fiscal Year [Member]                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Removal of obligation to pay milestones     $ 10,000                  
Journey | DFD Agreement                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Research and Development Expense                 2,000 2,700 5,500 6,200
Expenses recognized                 $ 2,000 $ 2,700 $ 5,500 $ 6,200
Journey | DFD Agreement | Licensing Agreements [Member] | Dr. Reddy's Laboratories, Ltd [Member] | Achievement of Certain clinical Development, Regulatory and First Commercial Sale milestones [Member]                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Payments of milestones             $ 158,000          
Journey | Minimum | DFD Agreement | Licensing Agreements [Member] | Dr. Reddy's Laboratories, Ltd [Member] | Payable on Net Sales of the DFD-29 Product [Member]                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Sales royalties (as a percent)             10.00%          
Journey | Maximum | DFD Agreement | Licensing Agreements [Member] | Dr. Reddy's Laboratories, Ltd [Member] | Payable on Net Sales of the DFD-29 Product [Member]                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Sales royalties (as a percent)             15.00%          
Avenue                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Common shares issued (in shares)           3,636,365            
Shares issued           3,636,365            
Avenue | AnnJi Pharmaceutical Co                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Research and Development Expense         $ 900              
Common shares issued (in shares)         831,618              
Stock offering, price per share         $ 2.10              
Expenses recognized         $ 900              
Royalty Expense   $ 1,000   $ 2,000 $ 3,000              
Shares issued         831,618              
Avenue | AnnJi Pharmaceutical Co | Additional Indication Milestones                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Research and Development Expense $ 300                      
Common shares issued (in shares)         276,652              
Expenses recognized $ 300                      
Shares issued         276,652              
Avenue | AnnJi Pharmaceutical Co | Drug Development Milestones [Member]                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Payments of milestones         $ 27,500              
Avenue | AnnJi Pharmaceutical Co | Additional Sales Milestone Payments                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Payments of milestones         165,000              
Avenue | Minimum | AnnJi Pharmaceutical Co | Additional Sales Milestone Payments                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Revenue Recognition, Milestone Method, Revenue Recognized         75,000              
Avenue | Maximum | AnnJi Pharmaceutical Co | First Indication Milestones                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Payments of milestones         10,800              
Avenue | Maximum | AnnJi Pharmaceutical Co | Additional Sales Milestone Payments                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Revenue Recognition, Milestone Method, Revenue Recognized         750,000              
Avenue | Maximum | DFD Agreement | AnnJi Pharmaceutical Co | Additional Indication Milestones                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Payments of milestones         $ 14,500              
Checkpoint | Collaboration agreement regarding Antibodies discoveries and optimization | Adimab                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Payments of milestones               $ 2,200        
Milestone payable upon various filings for regulatory approvals to commercialize the product               $ 2,500